Gamaleya Research Institute 
Welcome,         Profile    Billing    Logout  
  Products    Diseases    Products    Trials    News 


«12...56789101112131415...3233»
  • ||||||||||  Sputnik-V (Gam-COVID-Vac Lyo) / Gamaleya Research Institute
    Enrollment closed, Trial completion date, Trial primary completion date:  Sputnik-HD: Immune Response in Dialysis Patients Vaccinated Against COVID-19 (clinicaltrials.gov) -  Sep 27, 2021   
    P=N/A,  N=42, Active, not recruiting, 
    Recruiting --> Active, not recruiting | Trial completion date: Oct 2021 --> Jan 2022 | Trial primary completion date: Sep 2021 --> Jan 2022
  • ||||||||||  Vaxzevria (ChAdOx1-S recombinant) / Oxford Biomedica, Emergent Biosolutions, Jenner Institute, Vaccitech, AstraZeneca, University of Oxford, Sputnik-V (Gam-COVID-Vac Lyo) / Gamaleya Research Institute
    [VIRTUAL] Safety of COVID-19 vaccines in patients with multiple sclerosis from Latin America (ePoster Library) -  Sep 23, 2021 - Abstract #ECTRIMS2021ECTRIMS_2384;    
    COVID-19 vaccines seem to be safe for pwMS from Latin America. No major safety signals appeared in this patient-reported study.
  • ||||||||||  Sputnik-V (Gam-COVID-Vac Lyo) / Gamaleya Research Institute
    [VIRTUAL] Acute disseminated encephalomyelitis following vaccination against SARS-CoV-2: a case report (ePoster Library) -  Sep 23, 2021 - Abstract #ECTRIMS2021ECTRIMS_1560;    
    Our patient met the ADEM diagnostic criteria set by the International Pediatric MS Study Group and alternative diagnoses were excluded. Although a plausible relationship was not demonstrated, the possibility of an association with vaccine is suspected.
  • ||||||||||  Sputnik-V (Gam-COVID-Vac Lyo) / Gamaleya Research Institute
    Wann kommt Sputnik V? (Twitter) -  Sep 20, 2021   
  • ||||||||||  Sputnik-V (Gam-COVID-Vac Lyo) / Gamaleya Research Institute
    Approve Sputnik V!!!!! (Twitter) -  Sep 20, 2021   
  • ||||||||||  Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
    Clinical, Journal:  Acute relapse and poor immunization following COVID-19 vaccination in a rituximab-treated multiple sclerosis patient. (Pubmed Central) -  Sep 17, 2021   
    Meanwhile, clinicians should raise awareness among their patients regarding the potentially limited efficacy of COVID-19 vaccination in those treated with anti-CD20 treatments. After careful, individualized risk-benefit assessments, planning a delay/pause in such treatments to create a time window for patients to receive the vaccine and develop anti-SARS-CoV-2 immunity may be recommended.
  • ||||||||||  Vaxzevria (ChAdOx1-S recombinant) / Oxford Biomedica, Emergent Biosolutions, Jenner Institute, Vaccitech, AstraZeneca, University of Oxford, Sputnik-V (Gam-COVID-Vac Lyo) / Gamaleya Research Institute
    Journal:  A rational strategy to support approved COVID-19 vaccines prioritization. (Pubmed Central) -  Sep 17, 2021   
    In this paper, a knowledge-based or rational strategy is employed to perform a prioritization matrix of approved COVID-19 vaccines: BBIBP-CorV, JANSSEN, CORONAVAC, SPUTNIK V, MODERNA, PFIZER, and VAXZEVRIA, based on those proposed criteria by WHO, related to safety, efficacy, stability, implementation, and availability. We found that JANSSEN vaccine is the one with the highest score in the present study, but our analysis suggests that the WHO criteria could be more useful if they are considered separately, taking into account the social, demographic and economic characteristics of each country.
  • ||||||||||  Sputnik-V (Gam-COVID-Vac Lyo) / Gamaleya Research Institute
    Clinical, Journal:  Can children of the Sputnik V vaccine recipients become symptomatic? (Pubmed Central) -  Sep 17, 2021   
    In this study, we observed that 15/18 (83%) of the children of the Sputnik V recipients became symptomatic and developed transient fever and chills for 1-2 days starting after 2-5 days following the vaccination of their parents that can be related to an Adenovirus infection. To our knowledge, this is the first study reporting such symptoms in the children of Sputnik V recipients, and the results should be validated by larger studies.
  • ||||||||||  Sputnik-V (Gam-COVID-Vac Lyo) / Gamaleya Research Institute
    Enrollment change:  OLSTAD: Study of Gam-COVID-Vac in Adolescents (clinicaltrials.gov) -  Sep 16, 2021   
    P2/3,  N=3000, Recruiting, 
    No abstract available N=350 --> 3000
  • ||||||||||  Sputnik-V (Gam-COVID-Vac Lyo) / Gamaleya Research Institute
    Where is Sputnik V? (Twitter) -  Sep 15, 2021   
  • ||||||||||  Sputnik-V (Gam-COVID-Vac Lyo) / Gamaleya Research Institute
    Sputnik V where is? (Twitter) -  Sep 11, 2021